Back to Search
Start Over
Sarepta, BioMarin settle dispute
- Source :
- C&EN Global Enterprise. 95:13-13
- Publication Year :
- 2017
- Publisher :
- American Chemical Society (ACS), 2017.
-
Abstract
- Sarepta will pay BioMarin $35 million to settle a lengthy patent dispute over treatments for Duchenne muscular dystrophy (DMD). The companies’ legal tangle centered on patents related to antisense oligonucleotides that allow a missing muscular protein to be made in boys with DMD. BioMarin also scores a 5% royalty on U.S. sales of exon-skipping compounds 51, 45, and 53 and an 8% royalty on European sales. The deal helps BioMarin recoup some of the roughly $840 million it paid in 2014 to acquire Prosensa, a Dutch biotech firm whose lead DMD drug, drisapersen, was later rejected by FDA.
Details
- ISSN :
- 24747408
- Volume :
- 95
- Database :
- OpenAIRE
- Journal :
- C&EN Global Enterprise
- Accession number :
- edsair.doi...........4399a87e89c6ad254a1d6b1d3698e926